Oruka Therapeutics (NASDAQ:ORKA) Hits New 1-Year High – Time to Buy?

Oruka Therapeutics, Inc. (NASDAQ:ORKA) reached a new 52-week high on Thursday . The company traded as high as $42.88 and last traded at $40.80, with a volume of 956419 shares trading hands. The stock had previously closed at $41.31.

Analyst Upgrades and Downgrades

ORKA has been the subject of a number of research reports. Wall Street Zen upgraded Oruka Therapeutics from a “sell” rating to a “hold” rating in a report on Monday. BTIG Research restated a “buy” rating and issued a $73.00 target price on shares of Oruka Therapeutics in a research report on Friday, March 13th. Leerink Partners upped their target price on Oruka Therapeutics from $58.00 to $86.00 and gave the stock an “outperform” rating in a research note on Monday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oruka Therapeutics in a research report on Thursday, January 22nd. Finally, UBS Group began coverage on shares of Oruka Therapeutics in a research note on Wednesday, January 7th. They set a “buy” rating and a $50.00 price target on the stock. Ten equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $59.60.

Oruka Therapeutics Price Performance

The firm’s 50 day simple moving average is $33.77 and its two-hundred day simple moving average is $28.14. The firm has a market capitalization of $2.02 billion, a P/E ratio of -21.94 and a beta of -0.38.

Oruka Therapeutics (NASDAQ:ORKA) last announced its quarterly earnings data on Thursday, March 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.16. As a group, equities research analysts forecast that Oruka Therapeutics, Inc. will post -3.41 EPS for the current year.

Insider Activity at Oruka Therapeutics

In other Oruka Therapeutics news, insider Joana Goncalves sold 7,641 shares of the business’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $40.91, for a total value of $312,593.31. Following the completion of the sale, the insider owned 33,377 shares in the company, valued at approximately $1,365,453.07. The trade was a 18.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Lawrence Otto Klein sold 1,729 shares of the stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $41.30, for a total value of $71,407.70. Following the sale, the chief executive officer directly owned 927,309 shares of the company’s stock, valued at approximately $38,297,861.70. This trade represents a 0.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 30,765 shares of company stock worth $1,063,845. 24.69% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in ORKA. Legal & General Group Plc bought a new stake in Oruka Therapeutics during the 2nd quarter valued at $28,000. Ameritas Investment Partners Inc. purchased a new stake in Oruka Therapeutics during the 2nd quarter valued at $31,000. BNP Paribas Financial Markets grew its holdings in Oruka Therapeutics by 464.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 2,803 shares of the company’s stock worth $31,000 after acquiring an additional 2,306 shares during the last quarter. Royal Bank of Canada grew its holdings in Oruka Therapeutics by 47.2% in the 4th quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock worth $34,000 after acquiring an additional 365 shares during the last quarter. Finally, Los Angeles Capital Management LLC purchased a new position in shares of Oruka Therapeutics in the fourth quarter valued at about $37,000. Institutional investors own 56.44% of the company’s stock.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.